{
    "clinical_study": {
        "@rank": "55292", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Low dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Mid dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "High dose", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Comparison of efficacy of APD403 at preventing delayed sickness in patients who have\n      received cancer chemotherapy"
        }, 
        "brief_title": "Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy", 
        "condition": "CINV", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          -  Male or female patients \u2265 18 years of age\n\n          -  Ability and willingness to give written informed consent\n\n          -  Patients scheduled to receive, on day 1 of their chemotherapy, either: (i) a first\n             cisplatin chemotherapy infusion at a dose of \u226570 mg/m2 (males and females); or (ii) a\n             first infusion of cyclophosphamide at a dose of 500-1500 mg/m2 in combination with\n             either epirubicin at a dose of 60-100 mg/m2 or doxorubicin at a dose of 40-60 mg/m2\n             (females only)\n\n          -  Karnofsky performance score \u2265 60%\n\n          -  Adequate cardiac, hepatic and renal function\n\n               -  QTc interval < 500 ms\n\n               -  Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) < 5 x\n                  upper limit normal (ULN)\n\n               -  Bilirubin < 5 x ULN\n\n               -  Creatinine < 3 x ULN\n\n          -  Adequate haematological function\n\n               -  Haemoglobin \u2265 8 g/dL\n\n               -  White blood count \u2265 3.0 x 109/L\n\n               -  Platelet count \u2265 100 x 109/L\n\n          -  For females of child-bearing potential: ability and willingness to use a highly\n             effective form of contraception (e.g., abstinence from sexual intercourse, surgical\n             sterilisation (of subject or partner) or a double-barrier method of contraception\n             such as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in\n             conjunction with partner's use of a condom) during the study and for a period of at\n             least 48 hours afterwards\n\n        Exclusion Criteria\n\n          -  Patients scheduled to receive, prior to or in the 120 hours after cisplatin or AC,\n             any other chemotherapeutic agent with a high or moderate emetic risk\n\n          -  Patients who have previously received anti-neoplastic chemotherapy\n\n          -  Patients scheduled to receive paclitaxel or docetaxel during the first cycle of their\n             chemotherapy\n\n          -  Patients undergoing abdominal or pelvic irradiation within 48 hours prior to\n             screening or scheduled to receive abdominal or pelvic irradiation between screening\n             and 24 hours after cisplatin or AC administration\n\n          -  Patients with a known prolactin-dependent tumour (e.g. pituitary gland prolactinoma\n             or confirmed prolactin-dependent breast cancer) or phaeochromocytoma\n\n          -  Patients with a pre-existing vestibular disorder\n\n          -  Patients being treated with regular anti-emetic therapy including corticosteroids\n\n          -  Patients receiving inhaled corticosteroids, unless started more than one month prior\n             to the expected date of study entry"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "315", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01857232", 
            "org_study_id": "DN10016"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Control", 
                    "Low dose", 
                    "Mid dose", 
                    "High dose"
                ], 
                "intervention_name": "Ondansetron, dexamethasone, fosaprepitant", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Ondansetron", 
                "Aprepitant", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 17, 2013", 
        "number_of_arms": "5", 
        "official_title": "Randomised, Double-blind, Dose-finding Phase II Study to Assess the Efficacy of APD403 in the Prevention of Nausea and Vomiting Caused by Cisplatin- or Anthracycline/Cyclophosphamide (AC)-Based Chemotherapy", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Denmark: Danish Medicines Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Complete Response", 
            "safety_issue": "No", 
            "time_frame": "24-120 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01857232"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Acacia Pharma Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Acacia Pharma Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}